Background: HIV posttreatment controllers are rare individuals who start antiretroviral therapy (ART), but maintain HIV suppression after treatment interruption. The frequency of posttreatment control and posttreatment interruption viral dynamics have not been well characterized. Methods: Posttreatment controllers were identified from 14 studies and defined as individuals who underwent treatment interruption with viral loads ≤400 copies/mL at two-thirds or more of time points for ≥24 weeks. Viral load and CD4+ cell dynamics were compared between posttreatment controllers and noncontrollers. Results: Of the 67 posttreatment controllers identified, 38 initiated ART during early HIV infection. Posttreatment controllers were more frequently identified in those treated during early versus chronic infection (13% vs 4%, P < .001). In posttreatment controllers with weekly viral load monitoring, 45% had a peak posttreatment interruption viral load of ≥1000 copies/mL and 33% had a peak viral load ≥10000 copies/mL. Of posttreatment controllers, 55% maintained HIV control for 2 years, with approximately 20% maintaining control for ≥5 years. Conclusions: Posttreatment control was more commonly identified amongst early treated individuals, frequently characterized by early transient viral rebound and heterogeneous durability of HIV remission. These results may provide mechanistic insights and have implications for the design of trials aimed at achieving HIV remission.
Background: HIV posttreatment controllers are rare individuals who start antiretroviral therapy (ART), but maintain HIV suppression after treatment interruption. The frequency of posttreatment control and posttreatment interruption viral dynamics have not been well characterized. Methods: Posttreatment controllers were identified from 14 studies and defined as individuals who underwent treatment interruption with viral loads ≤400 copies/mL at two-thirds or more of time points for ≥24 weeks. Viral load and CD4+ cell dynamics were compared between posttreatment controllers and noncontrollers. Results: Of the 67 posttreatment controllers identified, 38 initiated ART during early HIV infection. Posttreatment controllers were more frequently identified in those treated during early versus chronic infection (13% vs 4%, P < .001). In posttreatment controllers with weekly viral load monitoring, 45% had a peak posttreatment interruption viral load of ≥1000 copies/mL and 33% had a peak viral load ≥10000 copies/mL. Of posttreatment controllers, 55% maintained HIV control for 2 years, with approximately 20% maintaining control for ≥5 years. Conclusions: Posttreatment control was more commonly identified amongst early treated individuals, frequently characterized by early transient viral rebound and heterogeneous durability of HIV remission. These results may provide mechanistic insights and have implications for the design of trials aimed at achieving HIV remission.
Authors: Janine Maenza; Kenneth Tapia; Sarah Holte; Joanne D Stekler; Claire E Stevens; James I Mullins; Ann C Collier Journal: Antivir Ther Date: 2015-04-23
Authors: Richard H Haubrich; Sharon A Riddler; Heather Ribaudo; Gregory Direnzo; Karin L Klingman; Kevin W Garren; David L Butcher; James F Rooney; Diane V Havlir; John W Mellors Journal: AIDS Date: 2011-11-28 Impact factor: 4.177
Authors: J P Routy; P Vanhems; D Rouleau; C Tsoukas; E Lefèbvre; P Côté; R LeBlanc; B Conway; M Alary; J Bruneau; R P Sekaly Journal: J Acquir Immune Defic Syndr Date: 2000-08-15 Impact factor: 3.731
Authors: Boris Julg; Lynda Dee; Jintanat Ananworanich; Dan H Barouch; Katharine Bar; Marina Caskey; Donn J Colby; Liza Dawson; Krista L Dong; Karine Dubé; Joseph Eron; John Frater; Rajesh T Gandhi; Romas Geleziunas; Philip Goulder; George J Hanna; Richard Jefferys; Rowena Johnston; Daniel Kuritzkes; Jonathan Z Li; Udom Likhitwonnawut; Jan van Lunzen; Javier Martinez-Picado; Veronica Miller; Luis J Montaner; Douglas F Nixon; David Palm; Giuseppe Pantaleo; Holly Peay; Deborah Persaud; Jessica Salzwedel; Karl Salzwedel; Timothy Schacker; Virginia Sheikh; Ole S Søgaard; Serena Spudich; Kathryn Stephenson; Jeremy Sugarman; Jeff Taylor; Pablo Tebas; Caroline T Tiemessen; Randall Tressler; Carol D Weiss; Lu Zheng; Merlin L Robb; Nelson L Michael; John W Mellors; Steven G Deeks; Bruce D Walker Journal: Lancet HIV Date: 2019-03-15 Impact factor: 12.767
Authors: Zaza M Ndhlovu; Samuel W Kazer; Thandeka Nkosi; Funsho Ogunshola; Daniel M Muema; Gursev Anmole; Shayda A Swann; Amber Moodley; Krista Dong; Tarylee Reddy; Mark A Brockman; Alex K Shalek; Thumbi Ndung'u; Bruce D Walker Journal: Sci Transl Med Date: 2019-05-22 Impact factor: 17.956
Authors: Michael C Sneller; Erin D Huiting; Katherine E Clarridge; Catherine Seamon; Jana Blazkova; Jesse S Justement; Victoria Shi; Emily J Whitehead; Rachel F Schneck; Michael Proschan; Susan Moir; Anthony S Fauci; Tae-Wook Chun Journal: J Infect Dis Date: 2020-10-13 Impact factor: 5.226
Authors: Jillian S Y Lau; Miranda Z Smith; Brent Allan; Cipriano Martinez; Jennifer Power; Sharon R Lewin; James H McMahon Journal: AIDS Res Hum Retroviruses Date: 2019-12-02 Impact factor: 2.205